Nervous System Diseases

1,005 trials 421 recruiting

Filter these 1,005 trials by phase, country and sponsor.

Open in Search →

CAPSAPED Recruiting

2022-500265-27-00 Chronic postchirurgical or post-traumatic neuropathic p 5 2024-03-05
Montelukast as disease modifying treatment in mild-moderate Parkinson’s disease (MONTPARK), a double-blind randomized placebo-controlled pha… Recruiting

2023-504278-39-00 Parkinson's disease 4 2024-02-27
THC for chronic neuropathic pain Recruiting

2022-502343-35-00 Chronic neuropathic pain 4 2024-02-20
An Open-label Study of XEN1101 in Epilepsy Recruiting

2022-502282-24-00 Primary generalized tonic-clonic seizures 5 2024-02-14
Prospective, placebo-controlled clinical trial with Aconite Pain Oil in oncological patients under-going chemotherapy to prevent chemotherap… Recruiting

2022-502889-24-00 chemotherapy-induced polyneuropathy (CIPN) 5 2024-02-13
Ph1/2 study of AVB-101 in Subjects with Frontotemporal Dementia with Progranulin Mutations (FTD-GRN) Recruiting

2023-509444-10-00 Frontotemporal Dementia With Progranulin Mutations (FTD 7 2024-02-08
Treatment of Established Status Epilepticus in the Elderly - a prospective, randomized, double-blind comparative effectiveness trial Recruiting

2024-516634-35-00 Convulsive or nonconvulsive benzodiazepine-resistant (e 6 2024-02-01
First in human study in healthy volunteers and participants with Parkinsons disease with and without GBA1 mutations. Recruiting

2023-509158-68-00 Parkinson’s disease 1 2024-01-25
Neural Stem Cell Treatment for Amyotrophic Lateral Sclerosis: A multicenter, randomized placebo controlled and biological endpoints clinical… Recruiting

2024-518888-35-00 amyotrophic lateral sclerosis patients 4 2024-01-24
Prospective head-to-head comparison of cardiac [18F]-MFBG PET versus [123I]-MIBG SPECT in the differentiation between Parkinson’s disease an… Recruiting

2023-506508-18-00 Parkinson's disease 10 2024-01-19
Safety, pharmacokinetics and pharmacodynamics study of Leucettinib-21 in healthy subjects, Down Syndrom and Alzheimer patients Recruiting

2023-507075-22-00 A Phase 1, Randomized, Double-Blind, Placebo-Controlled 1 2024-01-05
Treatment of difficult-to-control epilepsy associated with tuberous sclerosis complex Recruiting

2024-520171-27-00 Refractory epilepsy in tuberous sclerosis complex 5 2023-12-18
Daridorexant to treat insomnia in patients with mild cognitive impairment and mild to moderate Alzheimer disease. Recruiting

2023-503301-10-00 Insomnia Disorder; SLEEP; Alzheimer Disease 6 2023-12-14
Multicenter, randomized, double-blind, parallel-group clinical trial to evaluate the efficacy and safety of Safinamide versus Rasagiline in … Recruiting

2023-503713-29-00 Fatigue symptoms associated with Parkinson´s Disease. 6 2023-12-13
An Extension study of the Long-Term Safety, Tolerability, and Efficacy of DNL310 in Participants With Mucopolysaccharidosis Type II (MPS II)… Recruiting

2023-503837-23-00 Mucopolysaccharidosis Type II [MPS II] 5 2023-12-12
Fremanezumab for pain in Complex Regional Pain Syndrome Recruiting

2022-503167-15-00 Complex Regional Pain Syndrome 4 2023-12-11
Cerebrolysin in CADASIL Recruiting

2024-513828-42-00 Cerebral Autosomal Dominant Arteriopathy with subcortic 4 2023-11-29
Efficacy and tolerability of the combination of anifrolumab (300 mg IV) and phototherapy versus phototherapy in adults with progressive viti… Recruiting

2024-512041-17-00 Patient with non-segmental (symmetrical) vitiligo with 4 2023-11-27
Safety and efficacy of botulinum toxin A (Botox) in patients with trigeminal neuralgia Recruiting

2023-504567-17-00 Trigeminal neuralgia 5 2023-11-15
Long-term neuropsychologic outcome of pre-emptive mTOR inhibitor treatment in children with tuberous sclerosis complex (TSC) under 4 months … Recruiting

2022-502332-39-00 Tuberous sclerosis complex (TSC) 4 2023-11-15
For patients with active multiple sclerosis, impact of annual versus semi-annual infusions of ocrelizumab after 2 years of initial treatment… Recruiting

2023-505420-62-00 Multiple sclerosis 5 2023-11-09
A Phase 3, prospective, randomized, double-blind, placebo-controlled, parallel group, international, multi-center study of rotigotine in com… Recruiting

2023-504602-11-00 Mild to moderate Alzheimer's disease 5 2023-10-25
Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3) Recruiting

2022-502281-25-00 Focal Onset Seizures 5 2023-09-27
A double-blind, placebo-controlled, randomised phase 1/2a study to evaluate the safety, tolerability and pharmacokinetics of single and rep… Recruiting

2023-505778-14-00 Age related hearing loss 7 2023-09-19